LeMaitre Vascular (NASDAQ:LMAT) Rating Lowered to Hold at StockNews.com

StockNews.com lowered shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a report issued on Friday.

Several other equities research analysts have also recently weighed in on LMAT. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. JMP Securities lifted their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Finally, Barrington Research upped their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Trading Up 0.4 %

NASDAQ:LMAT opened at $100.69 on Friday. The company has a 50-day moving average price of $97.65 and a 200-day moving average price of $89.54. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of 55.02, a P/E/G ratio of 2.47 and a beta of 0.93. LeMaitre Vascular has a 12 month low of $52.88 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular’s revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.33 earnings per share. Equities analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.79% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LMAT. Glenmede Trust Co. NA lifted its stake in LeMaitre Vascular by 1.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier’s stock valued at $976,000 after acquiring an additional 136 shares during the period. Summit Global Investments raised its holdings in shares of LeMaitre Vascular by 2.4% during the third quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock valued at $575,000 after purchasing an additional 146 shares during the last quarter. Shaker Investments LLC OH lifted its position in LeMaitre Vascular by 1.3% during the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock valued at $1,138,000 after purchasing an additional 175 shares during the period. NBC Securities Inc. boosted its holdings in LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in LeMaitre Vascular by 34.3% in the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 188 shares during the period. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.